Wall Street investment firm Jefferies Financial Group (JEF) is forecasting more than $10 billion in annual sales from Eli Lilly’s (LLY) new weight-loss pill that’s expected to hit the market in 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Akash Tewari, a top four-star-rated analyst at Jefferies, expects big sales from Eli Lilly’s weight-loss pill once it is approved by regulators in the first half of next year. Tewari, who is global head of biopharmaceutical research at Jefferies, forecasts peak sales of $25 billion for the weight-loss pill called Orforglipron.
The sales forecast for Eli Lilly’s weight-loss pill is more than the $18.84 billion generated by sales of rival Novo Nordisk’s (NVO) Ozempic medication last year, and more than double the $11.54 billion earned from Eli Lilly’s type 2 diabetes drug Mounjaro.
High Expectations
Expectations for Eli Lilly’s new weight-loss pill are running high after the company recently announced that it has all the data needed from clinical trials to apply for approval of the weight-loss pill from the U.S. Food and Drug Administration (FDA).
Management at Eli Lilly has said that they plan to officially launch the weight-loss pill around the world in summer 2026. Analysts such as Tewari at Jefferies see the pill as a game changer for weight-loss drugs, which are currently taken by injection using needles.
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Moderate Buy rating among 22 Wall Street analysts. That rating is based on 16 Buy and six Hold recommendations issued in the last three months. The average LLY price target of $904.76 implies 24.01% upside from current levels.
